Consequently, whether or not the MDSC activation is mediated by IL-13 from type II NKT cells, neutralizing TGF-β could interrupt autocrine and paracrine TGF-β loops driving suppression of tumor immunity (86, 88). The gene discussed is TGFB1; the disease is neoplasm.